Covidien releases successful drug-eluting balloon results; Dance Biopharm enters inhaled insulin joint venture;

> Covidien ($COV) released clinical data supporting its drug-coated balloon to treat lower limb blockages in peripheral artery disease patients. More

> Dance Biopharm entered into a joint venture with Harmony Asset to develop an inhaled insulin product in China and other Asian countries. Release

> Rexahn Pharmaceuticals ($RNN) in-licensed a novel oligonucleotide targeted drug delivery platform from Ohio State University, which has shown the ability to deliver compounds to cancer tumors in preclinical trials. Release

> Highly customizable coatings of foam-like polymers developed at the University of Rochester may be used for drug delivery, getting drugs into hard-to-reach places. Release

> Alliqua showed successful preclinical results for its investigational Lidocaine transdermal patch that compare favorably to current versions available on the market. Release